Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn
Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
Upon completion of the transaction, Biogen Hillerød will become the fourth biopharmaceutical contract development and manufacturing site of Fujifilm. The large-scale biologics manufacturing facility is installed with 6
Trazimera has been approved to treat human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Pfizer Oncology global president